Google
CTXR — CITIUS PHARMACEUTICALS INC (Healthcare >> Biotechnology)
CTXR FAQ
What is CTXR's ROE?
CITIUS PHARMACEUTICALS INC reports a Return on Equity (ROE) of -75.07%.
What is CTXR's dividend yield?
CITIUS PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is CTXR's Deepscope Quality Score?
Deepscope rates CTXR's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CTXR?
Deepscope's AI Timing Score for CTXR is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CTXR belong to?
CITIUS PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.56
Price
-0.03
(-5.65%)
Day Change
|
|
|---|
CTXR, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.56 |
| PBV / Sector |
0.23 / 4.71
GREAT
|
| Earning Per Share | -1.59 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.43 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-10 09:43:15 |
| Symbol | CTXR |
| Name | CITIUS PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 27.45 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 16.18 / 8,889.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11 Commerce Drive, Cranford, NJ, United States, 07016
Phone: 908 967 6677
Website: https://citiuspharma.com
Sector: Healthcare >> Biotechnology
Description: Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
